Kirsten J. Sowers

The paper identifies autologous neutralizing antibodies (aNAbs) as critical determinants of HIV-1 rebound after treatment interruption, defining quantitative limits on rebound-competent reservoirs.

The paper identifies frequent and genetically diverse CDRH3 topologies in the human antibody repertoire that can be targeted by vaccination to elicit broadly neutralizing antibodies.

This study isolates and characterizes V2 apex-directed neutralizing antibodies from SHIV-infected macaques, revealing structural and genetic features that enable broad neutralization.

This study shows that a single immunization with a germline-targeting trimer can induce broad HIV-1 neutralizing antibodies in a rhesus macaque bnAb mouse model.

This study shows that transient glycan deletions in SHIVs can induce CD4-binding site broadly neutralizing antibodies in macaques, offering a model for HIV vaccine design.

The paper identifies B cell priming as the main obstacle to developing HIV-1 V2 apex broadly neutralizing antibodies in SHIV-infected macaques.